ArticleTherapeutic advances in medical oncology2025
Prognostic significance of HER2-low and HER2-zero status before and after neoadjuvant chemotherapy in patients with HER2-negative breast cancer.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diet, hormones, and breast cancer: biomarker-guided assessment of risk and prognosis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Changes in human epidermal growth factor receptor 2 (HER2) status following neoadjuvant chemotherapy (NAC) indicate tumor heterogeneity. Objective: Investigating the prognostic impact of the transition between HER2-low and HER2-zero may help eliminate the confounding effects of heterogeneity, thereby clarifying the prognostic significance of HER2-low status. Design: Retrospective analysis. Methods: Data were collected from patients with HER2-negative, early-stage breast cancer who did not achieve a pathological complete response after NAC. Cox regression models and Kaplan-Meier survival curves were employed to analyze disease-free survival (DFS) and overall survival (OS). Results: A total of 744 patients were included in the analysis, including 207 with HER2-zero and 537 with HER2-low pre-NAC. Among these, 46.9% (97/207) of the patients with HER2-zero transitioned to HER2-low, whereas 14.7% (79/537) of those with HER2-low transitioned to HER2-zero. Based on the HER2 status pre-NAC, there was no difference in prognosis between the HER2-zero and HER2-low groups. Patients with constant HER2-zero status had poorer OS than those who transitioned from HER2-zero to HER2-low ( Conclusion: HER2 transitions between low and zero expressions were frequently observed after NAC, exhibiting heterogeneity of the HER2 expression. Except for the worst OS in the constant HER2-zero, hormone receptor-negative subgroup, no significant differences were observed in the DFS and OS with respect to the changes of HER2-zero and HER2-low groups. The prognostic significance of HER2-zero and HER2-low changes after NAC requires further exploration through prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.